DOCSLIB.ORG

Multidisciplinary Study of a New Clc-1 Mutation Causing Myotonia Congenita

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Multidisciplinary Study of a New Clc-1 Mutation Causing Myotonia Congenita View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della Ricerca - Università di Pisa THE JOURNAL • RESEARCH • www.fasebj.org Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies Paola Imbrici,*,1 Concetta Altamura,* Giulia Maria Camerino,* Giuseppe Felice Mangiatordi,* Elena Conte,* † † ‡ Lorenzo Maggi, Raffaella Brugnoni, Kejla Musaraj,* Roberta Caloiero,* Domenico Alberga, § † Rene` Massimiliano Marsano, Giulia Ricci,{ Gabriele Siciliano,{ Orazio Nicolotti,* Marina Mora, † † Pia Bernasconi, Jean-Francois Desaphy,k Renato Mantegazza, and Diana Conte Camerino* ‡ *Department of Pharmacy, Drug Sciences, Department of Physics “M. Merlin,” Istituto Nazionale di Fisica Nucleare and Centro di Tecnologie Innovative per la Rilevazione e l’Elaborazione del Segnale, §Department of Biology, and kDepartment of Biomedical Sciences and Human † Oncology, University of Bari “Aldo Moro,” Bari, Italy; Division of Neurology, Neuroimmunology and Neuromuscular Diseases Unit, Istituti di Ricovero e Cura a Carattere Scientifico Fondazione Istituto Neurologico “Carlo Besta,” Milan, Italy; and {Department of Clinical and Experimental Medicine, Section of Neurology, University of Pisa, Pisa, Italy ABSTRACT: Myotonia congenita is an inherited disease that is characterized by impaired muscle relaxation after con- traction caused by loss-of-function mutations in the skeletal muscle ClC-1 channel. We report a novel ClC-1 mutation, T335N, that is associated with a mild phenotype in 1 patient, located in the extracellular I-J loop. The purpose of this study was to provide a solid correlation between T335N dysfunction and clinical symptoms in the affected patient as well as to offer hints for drug development. Our multidisciplinary approach includes patch-clamp electrophysiology on T335N and ClC-1 wild-type channels expressed in tsA201 cells, Western blot and quantitative PCR analyses on muscle biopsies from patient and unaffected individuals, and molecular dynamics simulations using a homology model of the ClC-1 dimer. T335N channels display reduced chloride currents as a result of gating alterations rather than altered surface expression. Molecular dynamics simulations suggest that the I-J loop might be involved in conformational changes that occur at the dimer interface, thus affecting gating. Finally, the gene expression profile of T335N carrier showed a diverse expression of K+ channel genes, compared with control individuals, as potentially contributing to the phenotype. This experimental paradigm satisfactorily explained myotonia in the patient. Furthermore, it could be relevant to the study and therapy of any channelopathy.—Imbrici, P., Altamura, C., Camerino, G. M., Mangiatordi, G. F., Conte, E., Maggi, L., Brugnoni, R., Musaraj,K.,Caloiero,R.,Alberga,D.,Marsano,R.M.,Ricci,G.,Siciliano,G.,Nicolotti,O.,Mora,M.,Bernasconi,P., Desaphy, J.-F., Mantegazza, R., Camerino, D. C. Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: a paradigm to understand and treat ion channelopathies. FASEB J. 30, 3285–3295 (2016). www.fasebj.org KEY WORDS: chloride channel • gene expression • molecular dynamics • patch-clamp • skeletal muscle Myotonia congenita (MC), in its dominant and recessive age of onset and is more severe. Dominant MC encom- form, is the most common skeletal muscle ion channel- passes a wider range of symptoms, from subclinical to opathy and is characterized by muscle stiffness after moderately severe manifestations (1, 2). MC is caused by voluntary effort (1). Usually, recessive MC has an early loss-of-function mutations in the CLCN1 gene that en- codes the voltage-gated chloride channel, ClC-1, which maintains the large shunting chloride conductance of ABBREVIATIONS: 3D, 3-dimensional; AA, atom acceptor; AD, atom donor; H-bond, hydrogen bond; MC, myotonia congenita; MD, molecular dy- muscle fibers (3). namics; Po, open probability; qPCR, quantitative PCR; TBS, Tris-buffered As for other ion channel diseases, functional studies saline; VMD, visual molecular dynamics; WT, wild-type using heterologous expression systems have been decisive 1 Correspondence: Department of Pharmacy, Drug Sciences, University of Bari to clarify molecular mechanisms underlying myotonia. “Aldo Moro,” Via Orabona 4, 70125 Bari, Italy. E-mail: paola.imbrici@uniba Indeed, in a majority of cases, biophysical characterization This is an Open Access article distributed under the terms of the Creative of expressed ClC-1 mutants satisfactorily demonstrated Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons. that specific ClC-1 defects were the obvious culprit for org/licenses/by/4.0/) which permits unrestricted use, distribution, and re- production in any medium, provided the original work is properly cited. clinical features of patients (4, 5). In vitro studies proved that 2 recessive mutations must be present, each affecting doi: 10.1096/fj.201500079R This article includes supplemental data. Please visit http://www.fasebj.org to the function of 1 allele, to reduce chloride currents suffi- obtain this information. ciently to produce myotonia (6, 7). In contrast, most ClC-1 0892-6638/16/0030-3285 © The Author(s) 3285 Downloaded from www.fasebj.org by (131.114.70.49) on December 11, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 3285-3295. dominant mutants exert a dominant-negative effect on the MATERIALS AND METHODS associated wild-type (WT) subunit in the heterodimeric channel (8); however, in some cases, results of functional Mutagenesis and expression of hClC-1 WT and studies of expressed mutant channels were inadequate to mutant channels predict a clear correlation between genotype and clinical . symptoms, essential to define the most appropriate The c.1004C A mutation was introduced into the plasmid pRcCMV-hClC-1 that contained the full-length WT hClC-1 treatment (9). For instance, myotonic individuals who cDNA by using the QuikChange site-directed mutagenesis kit carry the same ClC-1 mutation can have markedly var- (Stratagene, Santa Clara, CA, USA), as previously described (5). iable expressivity (10). Some mutations may appear re- The complete coding region of the cDNA was sequenced to ex- cessive or dominant in different families, whereas others clude polymerase errors. tsA201 cells were transiently trans- show incomplete penetrance. Several recessive muta- fected with a mixture of hClC-1 WT or T335N (5 mg) and CD8 m tions show no evidence of defective function in heterol- reporter plasmids (1 g) by using the calcium phosphate pre- ogous systems (5, 11, 12), and some dominant mutations cipitation method. Only cells that were decorated with anti-CD8 antibody–coated microbeads (Dynabeads M450; Thermo Fisher do not induce the expected dominant-negative effect on – Scientific Life Sciences, Waltham, MA, USA) were used for patch- the WT subunit (4 6). These evidences suggest that, as clamp recordings. in the case of other monogenic disorders, environ- mental factors and genetic background of patients may Electrophysiology and data analysis further contribute to variability of MC phenotype (10, 13). Thus, to fulfill the limits of heterologous expres- Standard whole-cell patch-clamp recordings were performed at sion, we recently studied muscle biopsies from pa- room temperature (;20°C) by using an Axopatch 200B amplifier tients with recessive MC to identify possible disease (Axon Instruments, Sunnyvale, CA, USA) (5). We measured the modifiers among genes that are involved in muscle I-V relationship and overall apparent open probability in high- excitability (11), demonstrating that biologic samples chloride (134 mM) intracellular solutions to enhance current from affected individuals can yield valuable informa- amplitude and in more physiologic low internal chloride (4 mM) tion for understanding of the myotonic phenotype. solutions. Composition of the extracellular solution was as fol- lows (in mM): 140 NaCl, 4 KCl, 2 CaCl2,1MgCl2, and 5 HEPES, Muscle biopsies can also help achieve a proper di- pH 7.4 with NaOH. High-chloride pipette solution contained (in agnosis of myotonia (14). mM): 130 CsCl, 2 MgCl2, 5 EGTA, and 10 HEPES, pH 7.4 with Another unsolved issue regarding myotonia, which is CsOH. In this condition, cells were clamped at the holding po- common to a significant number of ion channelopathies, is tential of 0 mV. In the low-chloride internal solution, cesium lack of a specific therapy. Myotonic patients are usually chloride was substituted by cesium glutamate and cells were clamped at the holding potential of –95 mV. Pipettes were pulled administered symptomatic treatment, including mex- ; V iletine, a sodium channel blocker, or acetazolamide, a from borosilicate glass and had 2.5 M resistance. Currents were low-pass filtered at 2 kHz and digitized with sampling rates carbonic anhydrase inhibitor, with limited side effects – of 50 kHz by using the Digidata 1440A AD/DA converter (Axon and high percentages of nonresponders (15 17). Ab- Instruments). In high-chloride solution, 400-ms voltage steps sence of direct ClC-1 opener prompts identification of were applied from 2200 mV to +150 mV in 10-mV intervals, each novel targets and development of new drugs. In this re- followed by a 100-ms voltage step at 2105 mV, where tail cur- spect, analysis of patients’ muscle biopsies, together with rents were measured. In low-chloride solution, currents
Load more

Recommended publications
  • Spectrum of CLCN1 Mutations in Patients with Myotonia Congenita in Northern Scandinavia
    European Journal of Human Genetics (2001) 9, 903 ± 909 ã 2001 Nature Publishing Group All rights reserved 1018-4813/01 $15.00 www.nature.com/ejhg ARTICLE Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia Chen Sun*,1, Lisbeth Tranebjñrg*,1, Torberg Torbergsen2,GoÈsta Holmgren3 and Marijke Van Ghelue1,4 1Department of Medical Genetics, University Hospital of Tromsù, Tromsù, Norway; 2Department of Neurology, University Hospital of Tromsù, Tromsù, Norway; 3Department of Clinical Genetics, University Hospital of UmeaÊ, UmeaÊ,Sweden;4Department of Biochemistry, Section Molecular Biology, University of Tromsù, Tromsù, Norway Myotonia congenita is a non-dystrophic muscle disorder affecting the excitability of the skeletal muscle membrane. It can be inherited either as an autosomal dominant (Thomsen's myotonia) or an autosomal recessive (Becker's myotonia) trait. Both types are characterised by myotonia (muscle stiffness) and muscular hypertrophy, and are caused by mutations in the muscle chloride channel gene, CLCN1. At least 50 different CLCN1 mutations have been described worldwide, but in many studies only about half of the patients showed mutations in CLCN1. Limitations in the mutation detection methods and genetic heterogeneity might be explanations. In the current study, we sequenced the entire CLCN1 gene in 15 Northern Norwegian and three Northern Swedish MC families. Our data show a high prevalence of myotonia congenita in Northern Norway similar to Northern Finland, but with a much higher degree of mutation heterogeneity. In total, eight different mutations and three polymorphisms (T87T, D718D, and P727L) were detected. Three mutations (F287S, A331T, and 2284+5C4T) were novel while the others (IVS1+3A4T, 979G4A, F413C, A531V, and R894X) have been reported previously.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Difference in Allelic Expression of the CLCN1 Gene and the Possible Influence on the Myotonia Congenita Phenotype
    European Journal of Human Genetics (2004) 12, 738–743 & 2004 Nature Publishing Group All rights reserved 1018-4813/04 $30.00 www.nature.com/ejhg ARTICLE Difference in allelic expression of the CLCN1 gene and the possible influence on the myotonia congenita phenotype Morten Dun1*, Eskild Colding-Jrgensen2, Morten Grunnet3,5, Thomas Jespersen3, John Vissing4 and Marianne Schwartz1 1Department of Clinical Genetics, 4062, University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark; 2Department of Clinical Neurophysiology 3063,University Hospital, Rigshospitalet, Blegdamsvej 9, DK- 2100 Copenhagen, Denmark; 3Department of Medical Physiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark; 4Department of Neurology and The Copenhagen Muscle Research Center, University Hospital, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark Mutations in the CLCN1 gene, encoding a muscle-specific chloride channel, can cause either recessive or dominant myotonia congenita (MC). The recessive form, Becker’s myotonia, is believed to be caused by two loss-of-function mutations, whereas the dominant form, Thomsen’s myotonia, is assumed to be a consequence of a dominant-negative effect. However, a subset of CLCN1 mutations can cause both recessive and dominant MC. We have identified two recessive and two dominant MC families segregating the common R894X mutation. Real-time quantitative RT-PCR did not reveal any obvious association between the total CLCN1 mRNA level in muscle and the mode of inheritance, but the dominant family with the most severe phenotype expressed twice the expected amount of the R894X mRNA allele. Variation in allelic expression has not previously been described for CLCN1, and our finding suggests that allelic variation may be an important modifier of disease progression in myotonia congenita.
    [Show full text]
  • Comprehensive Exonic Sequencing of Known Ataxia Genes in Episodic Ataxia
    biomedicines Article Comprehensive Exonic Sequencing of Known Ataxia Genes in Episodic Ataxia Neven Maksemous, Heidi G. Sutherland, Robert A. Smith, Larisa M. Haupt and Lyn R. Griffiths * Genomics Research Centre, Institute of Health and Biomedical Innovation (IHBI), School of Biomedical Sciences, Queensland University of Technology (QUT), Q Block, 60 Musk Ave, Kelvin Grove Campus, Brisbane, Queensland 4059, Australia; [email protected] (N.M.); [email protected] (H.G.S.); [email protected] (R.A.S.); [email protected] (L.M.H.) * Correspondence: lyn.griffi[email protected]; Tel.: +61-7-3138-6100 Received: 4 May 2020; Accepted: 21 May 2020; Published: 25 May 2020 Abstract: Episodic Ataxias (EAs) are a small group (EA1–EA8) of complex neurological conditions that manifest as incidents of poor balance and coordination. Diagnostic testing cannot always find causative variants for the phenotype, however, and this along with the recently proposed EA type 9 (EA9), suggest that more EA genes are yet to be discovered. We previously identified disease-causing mutations in the CACNA1A gene in 48% (n = 15) of 31 patients with a suspected clinical diagnosis of EA2, and referred to our laboratory for CACNA1A gene testing, leaving 52% of these cases (n = 16) with no molecular diagnosis. In this study, whole exome sequencing (WES) was performed on 16 patients who tested negative for CACNA1A mutations. Tiered analysis of WES data was performed to first explore (Tier-1) the ataxia and ataxia-associated genes (n = 170) available in the literature and databases for comprehensive EA molecular genetic testing; we then investigated 353 ion channel genes (Tier-2).
    [Show full text]
  • Chloride Channelopathies Rosa Planells-Cases, Thomas J
    Chloride channelopathies Rosa Planells-Cases, Thomas J. Jentsch To cite this version: Rosa Planells-Cases, Thomas J. Jentsch. Chloride channelopathies. Biochimica et Biophysica Acta - Molecular Basis of Disease, Elsevier, 2009, 1792 (3), pp.173. 10.1016/j.bbadis.2009.02.002. hal- 00501604 HAL Id: hal-00501604 https://hal.archives-ouvertes.fr/hal-00501604 Submitted on 12 Jul 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ÔØ ÅÒÙ×Ö ÔØ Chloride channelopathies Rosa Planells-Cases, Thomas J. Jentsch PII: S0925-4439(09)00036-2 DOI: doi:10.1016/j.bbadis.2009.02.002 Reference: BBADIS 62931 To appear in: BBA - Molecular Basis of Disease Received date: 23 December 2008 Revised date: 1 February 2009 Accepted date: 3 February 2009 Please cite this article as: Rosa Planells-Cases, Thomas J. Jentsch, Chloride chan- nelopathies, BBA - Molecular Basis of Disease (2009), doi:10.1016/j.bbadis.2009.02.002 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.
    [Show full text]
  • Supplementary Figure S1
    Supplementary Figure S1 Supplementary Figure S2 Supplementary Figure S3 Supplementary Figure S4 Supplementary Figure S5 Supplementary Figure S6 Supplementary Table 1: Baseline demographics from included patients Bulk transcriptomics Single cell transcriptomics Organoids IBD non-IBD controls IBD non-IBD controls IBD non-IBD controls (n = 351) (n = 51) (n = 6 ) (n= 5) (n = 8) (n =8) Disease - Crohn’s disease 193 (55.0) N.A. 6 (100.0) N.A. 0 (0.0) N.A. - Ulcerative colitis 158 (45.0) 0 (0.0) 8 (100.0) Women, n (%) 183 (52.1) 34 (66.7) 5 (83.3) 1 (20.0) 4 (50.0) 5 (62.5) Age, years, median [IQR] 41.8 (26.7 – 53.0) 57.0 (41.0 – 63.0) 42.7 (38.5 – 49.5) 71.0 (52.5 – 73.0) 41.3 (35.9 – 46.5) 45.0 (30.5 – 55.9) Disease duration, years, median [IQR] 7.9 (2.0 – 16.8) N.A. 13.4 (5.8 – 22.1) N.A 10.5 (7.8 – 12.7) N.A. Disease location, n (%) - Ileal (L1) 41 (21.3) 3 (50.0) - Colonic (L2) 23 (11.9) N.A. 0 (0.0) N.A. N.A. N.A. - Ileocolonic (L3) 129 (66.8) 3 (50.0) - Upper GI modifier (+L4) 57 (29.5) 0 (0.0) - Proctitis (E1) 13 (8.2) 1 (12.5) - Left-sided colitis (E2) 85 (53.8) N.A. N.A. N.A. 1 (12.5) N.A. - Extensive colitis (E3) 60 (38.0) 6 (75.0) Disease behaviour, n (%) - Inflammatory (B1) 95 (49.2) 0 (0.0) - Fibrostenotic (B2) 55 (28.5) N.A.
    [Show full text]
  • Clc-K Chloride Channels
    ClC-K chloride channels: emerging pathophysiology of Bartter syndrome type 3 Olga Andrini, Mathilde Keck, Rodolfo Briones, Stéphane Lourdel, Rosa Vargas-Poussou, Jacques Teulon To cite this version: Olga Andrini, Mathilde Keck, Rodolfo Briones, Stéphane Lourdel, Rosa Vargas-Poussou, et al.. ClC- K chloride channels: emerging pathophysiology of Bartter syndrome type 3. AJP Renal Physiology, American Physiological Society, 2015, 308 (12), pp.F1324-F1334. 10.1152/ajprenal.00004.2015. hal- 02453172 HAL Id: hal-02453172 https://hal.sorbonne-universite.fr/hal-02453172 Submitted on 24 Jan 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 ClC-K chloride channels: Emerging pathophysiology of Bartter syndrome type 3 2 3 4 Olga Andrini1,2, Mathilde Keck1,2, Rodolfo Briones3, Stéphane Lourdel1,2, Rosa Vargas-Poussou4,5 and 5 Jacques Teulon1,2. 6 7 1UPMC Université Paris 06, UMR_S 1138, Team 3, F-75006, Paris, France; 2INSERM, UMR_S 872, 8 Paris, France; 3Department of Theoretical and Computational Biophysics, Max-Planck Institute 9 for Biophysical Chemistry, 37077 Göttingen, Germany; 4Assistance Publique-Hôpitaux de Paris, 10 Hôpital Européen Georges Pompidou, Département de Génétique F-75908, Paris, France; 5Université 11 Paris-Descartes, Faculté de Médecine, F-75006, Paris, France.
    [Show full text]
  • Aquaporin 2 Mutations in Nephrogenic Diabetes Insipidus
    Aquaporin 2 Mutations in Nephrogenic Diabetes Insipidus Anne J. M. Loonen, MSc,* Nine V. A. M. Knoers,† Carel MD,H. vanPhD, Os, PhD,* and Peter M. T. Deen, PhD* Summary: Water reabsorption in the renal collecting duct is regulated by the antidiuretic hormone vasopressin (AVP). When the vasopressin V2 receptor, present on the basolateral site of the renal principal cell, becomes activated by AVP, aquaporin-2 (AQP2) water channels will be inserted in the apical membrane, and in this fashion, water can be reabsorbed from the pro-urine into the interstitium. The essential role of the vasopressin V2 receptor and AQP2 in the maintenance of body water homeostasis became clear when it was shown that mutations in their genes cause nephrogenic diabetes insipidus, a disorder in which the kidney is unable to concentrate urine in response to AVP. This review describes the current knowledge on AQP2 mutations in nephrogenic diabetes insipidus. Semin Nephrol 28:252-265 © 2008 Elsevier Inc. All rights reserved. Keywords: Autosomal nephrogenic diabetes insipidus, vasopressin, aquaporin-2 water channel, disease, routing he mammalian kidney has the abilitytransport to and mammalian osmoregulation. excrete or reabsorb free water indepen-Water balance is regulated by the combined T dent of changes in solute excretion.action of osmoreceptors, volume receptors, Physiologic studies have provided evidence thirstfor sensation, vasopressin, and water ex- the constitutive absorption of approximatelycretion or reabsorption by the kidney. To 90% of the glomerular filtration
    [Show full text]
  • Characterization of Renal Chloride Channel (CLCN5) Mutations in Dent’S Disease
    J Am Soc Nephrol 11: 1460–1468, 2000 Characterization of Renal Chloride Channel (CLCN5) Mutations in Dent’s Disease KATSUSUKE YAMAMOTO,* JEREMY P. D. T. COX,* THOMAS FRIEDRICH,† PAUL T. CHRISTIE,*‡‡ MARTIN BALD,‡ PETER N. HOUTMAN,§ MARTA J. LAPSLEY,ʈ LUDWIG PATZER,¶ MICHEL TSIMARATOS,# WILLIAM G VAN’T HOFF,** KANJI YAMAOKA,†† THOMAS J. JENTSCH,† and RAJESH V. THAKKER*‡‡ *MRC Molecular Endocrinology Group, Hammersmith Hospital, London, United Kingdom; †ZMNH Centre for Molecular Neurobiology, University of Hamburg, Germany; ‡Department of Paediatric Nephrology, University of Essen, Germany; §Department of Paediatrics, Leicester Royal Infirmary, United Kingdom; ʈDepartment of Chemical Pathology and Metabolism, St Helier Hospital, Surrey, United Kingdom; ¶Children’s Hospital “Jussuf Ibrahim,” Friedrich-Schiller University, Jena, Germany; #Department of Paediatric Nephrology, Children’s Hospital of the Timone, Marseille, France; **Department of Paediatric Nephrology, Great Ormond Street Hospital, London, United Kingdom; ††Department of Paediatrics, Osaka Prefectural Hospital, Osaka, Japan; and ‡‡Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom. Abstract. Dent’s disease is an X-linked renal tubular disorder endonuclease or sequence-specific oligonucleotide hybridiza- characterized by low molecular weight proteinuria, hypercal- tion analysis and were not common polymorphisms. The ciuria, nephrocalcinosis, nephrolithiasis, and renal failure. The frameshift deletions and nonsense mutation predict truncated disease is caused by mutations in a renal chloride channel gene, and inactivated CLC-5. The effects of the putative missense CLCN5, which encodes a 746 amino acid protein (CLC-5), Asp601Val mutant CLC-5 were assessed by heterologous ex- with 12 to 13 transmembrane domains. In this study, an addi- pression in Xenopus oocytes, and this revealed a chloride tional six unrelated patients with Dent’s disease were identified conductance that was similar to that observed for wild-type and investigated for CLCN5 mutations by DNA sequence CLC-5.
    [Show full text]
  • Mutations of CLCN5 in Japanese Children with Idiopathic Low Molecular Weight Proteinuria, Hypercalciuria and Nephrocalcinosis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 52 (1997), pp. 911—916 Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis NAOKO AKUTA, SARAH E.LLOYD,Tsrn IGARASHI, HIR0sHI SHIRAGA, TAKESHI MATSUYAMA, SEITAR0u Y0K0R0, JEREMY P. D. Cox, and RAJESH V. THAKKER MRC Molecular Endocrinology Group, MRC Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, London, England, United Kingdom; and Department of Pediatrics, Faculty of Medicine, The University of Tokyo, Pediatric Nephrology, Tokyo Women's Medical School, Department of Pediatrics, Fussa Hospital and Department of Pediatrics, Tokyo Metropolitan Fuchu Hospital Tokyo, Japan Mutations of CLCN5 in Japanese children with idiopathic low molec- encodes a 746 amino acid protein [6, 7]. CLCN5 belongs to a ular weight proteinuria, hypercalciuria and nephrocalcinosis. The annual family of voltage-gated chloride channel genes (CLCNO, CLCN1 urinary screening of Japanese children above three years of age has identified a progressive renal tubular disorder characterized by lowto CLCN7, and CLCNKa and CLCNKb) that encode proteins molecular weight proteinuria, hypercalciuria and nephrocalcinosis. The (CLC-0, CLC-1 to CLC-7, and CLC-Ka and CLC-Kb, respec- disorder has been observed in over 60 patients and has a familialtively) that have about 12 transmembrane domains (Fig. 1) [6, 8, predisposition. Mutations of a renal chloride channel gene, CLCN5, have 9]. These chloride channels have an important role in the control been reported in four such families, and we have undertaken studies in additional patients from 10 unrelated, non-consanguineous Japanese of membrane excitability, transepithelial transport and possibly families to further characterize such CLCN5 mutations and to ascertain cell volume [8].
    [Show full text]
  • Hypokalaemic Periodic Paralysis and Myotonia in a Patient With
    www.nature.com/scientificreports OPEN Hypokalaemic periodic paralysis and myotonia in a patient with homozygous mutation p.R1451L in Received: 5 April 2018 Accepted: 31 May 2018 NaV1.4 Published: xx xx xxxx Sushan Luo1,2, Marisol Sampedro Castañeda3, Emma Matthews3, Richa Sud3, Michael G. Hanna3, Jian Sun1, Jie Song1, Jiahong Lu1, Kai Qiao4, Chongbo Zhao1,5 & Roope Männikkö 3 Dominantly inherited channelopathies of the skeletal muscle voltage-gated sodium channel NaV1.4 include hypokalaemic and hyperkalaemic periodic paralysis (hypoPP and hyperPP) and myotonia. HyperPP and myotonia are caused by NaV1.4 channel overactivity and overlap clinically. Instead, hypoPP is caused by gating pore currents through the voltage sensing domains (VSDs) of NaV1.4 and seldom co-exists clinically with myotonia. Recessive loss-of-function NaV1.4 mutations have been described in congenital myopathy and myasthenic syndromes. We report two families with the NaV1.4 mutation p.R1451L, located in VSD-IV. Heterozygous carriers in both families manifest with myotonia and/or hyperPP. In contrast, a homozygous case presents with both hypoPP and myotonia, but unlike carriers of recessive NaV1.4 mutations does not manifest symptoms of myopathy or myasthenia. Functional analysis revealed reduced current density and enhanced closed state inactivation of the mutant channel, but no evidence for gating pore currents. The rate of recovery from inactivation was hastened, explaining the myotonia in p.R1451L carriers and the absence of myasthenic presentations in the homozygous proband. Our data suggest that recessive loss-of-function NaV1.4 variants can present with hypoPP without congenital myopathy or myasthenia and that myotonia can present even in carriers of homozygous NaV1.4 loss-of-function mutations.
    [Show full text]
  • The Molecular Basis for Dent's Disease: an X-Linked
    Proc. R. Coll. Physicians Edinb. 1997; 27: 167-177 THE MOLECULAR BASIS FOR DENT’S DISEASE: AN X-LINKED HYPERCALCIURIC NEPHROLITHIASIS DISORDER* R. V. Thakker,† MRC Molecular Endocrinology Group, MRC Clinical Sciences Centre, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London SUMMARY Renal stone disease, which affects 12% of males and 5% of females by the seventh decade, occurs as an inherited disorder in 45% of patients when it is most commonly associated with hypercalciuria. The biochemical basis for hereditary nephrolithiasis and hypercalciuria is unknown, and this has therefore been investigated by a ‘positional cloning’ approach. As a first step in this approach, the chromosomal location of Dent’s disease, which is an unusual form of the renal Fanconi syndrome was determined. An X-linked inheritance for Dent’s disease, which is characterised by a low molecular weight proteinuria, hypercalciuria, nephrocalcinosis, nephrolithiasis and renal failure, was indicated by the observation of a greater disease severity in males and an absence of male to male transmission in five British families. X-linked polymorphic genetic markers were used in linkage studies of these families and the gene was mapped to Xp11. In addition, in one family with Dent’s disease, a microdeletion involving the DNA probe M27β was identified. This microdeletion was further characterised by using yeast artificial chromosomes (YACs) and its size was estimated to be 515 Kb. A search for renal expressed genes from this region identified a novel gene encoding a chloride channel (CLCN5) with similarities to a family of voltage-gated chloride channels. Molecular genetic studies of CLCN5 demonstrated that mutations, which resulted in a functional loss, were associated with Dent’s disease.
    [Show full text]